LAS VEGAS, Dec. 7, 2006 (PRIME NEWSWIRE) -- Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs, announced that the U.S. Food and Drug Administration (FDA) has completed its regulatory review of our IND (Investigational New Drug) application for Caprospinol (SP-233), and has requested that additional information be submitted in support of the safety Caprospinol, prior to initiating Samaritan's proposed Phase I clinical study.
Samaritan filed an IND application for Caprospinol on October 30, 2006 and was subsequently granted an IND number by the FDA. To understand the IND processes go to: http://www.samaritanpharma.com/html/ctind.html
Caprospinol is a novel Alzheimer's drug candidate that Samaritan believes has the potential to clear beta-amyloid plaques from the brain; a problem that most researchers today believe, is the cause of Alzheimer's. Since Caprospinol could be a significant breakthrough in the treatment of Alzheimer's, Samaritan plans to provide the information requested by the FDA as quickly as possible, in order to continue moving our Caprospinol development program forward.
http://www.samaritanpharma.com/html/videos.html
Dr. Janet Greeson, CEO of Samaritan stated, "The filing of this IND speaks to the scientific merit of Caprospinol and the research collaboration we have with Georgetown University. This is the first IND as a result of our collaboration with Georgetown University and we have high hopes Caprospinol will make a significant contribution to the treatment of suffering Alzheimer patients."
Samaritan Pharmaceuticals: "We LIV . . . to Save Lives."
Samaritan is a small-cap Biotech, driven to discover, develop and commercialize innovative therapeutics for AIDS, Alzheimer's, Cancer and Heart disease patients. Look at www.samaritanpharma.com. Please register on Website so we can notify you of upcoming conference calls, news and events.
The Samaritan Pharmaceuticals Inc. logo is available at http://www.primezone.com/newsroom/prs/?pkgid=2670
Disclaimer
The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings and Website. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K/A filed November 2, 2006. The company undertakes no duty to update forward-looking statements.